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Abstract  
Background: The World Health Organization endorsed GeneXpert MTB/RIF (Xpert) assay for the diagnosis of 
tuberculosis (TB) and multidrug resistant tuberculosis (MDR-TB) in 2010. However, the practice of using this novel 
diagnostic method is still limited in a high TB and human immunodeficiency virus (HIV) burden settings, including 
Ethiopia. Therefore, we conducted this study aimed at describing the first implementation status of Xpert assay in 
the diagnosis of TB and MDR-TB at Felege Hiwot Referral Hospital (FHRH) and Debre Tabor General Hospital 
(DTGH), Northwest Ethiopia.  
Methods: We analyzed the records of 1922 (FHRH=544 and DTGH=1378) presumptive TB patients diagnosed using 
Xpert test from 1 November 2015 to 30 April 2016 at FHRH and DTGH, Northwest Ethiopia. All patients who had 
registered data on their sex, age, HIV status, presumptive MDR-TB status and Xpert results were included for 
analysis. Data were retrieved directly from GeneXpert result registration log book using data extraction sheet. Data 
were entered, cleaned, and analyzed using SPSS statistical software package; p < 0.05 was considered to be 
significant.  
Results: Overall Xpert assay properly diagnosed 14.6% of the cases (258/1922).  Among these, rifampicin (RIF) 
resistance was detected at 9.3% (24/258). In the studied settings, clinical data showed that 81.0% (1556/1922) of the 
cases were MDR- TB. Among the study subjects, 888 (46.2 %) of them were HIV positive. However, TB-HIV co-
infection rate was at 41.9% (108/258).  Of the total patients registered, 1005 (52.3%) of whom were males. The mean 
age of patients was 31.1 years with SD of 17.5. Significant predictors of the Xpert test were: age (p=0.000), sex 
(p=0.009), HIV status (p=0.003) and presumptive MDR-TB (p=0.000).  
Conclusions:  In the studied areas, large proportion of clinically TB suspected patients were wrongly diagnosed with 
MDR-TB. Therefore, the use of Xpert assay in health settings with no culture facility will decrease the unnecessary 
use of anti-TB drugs and improve rapid TB, and MDR-TB detection and proper management of the cases. [Ethiop. 
J. Health Dev.  2016;30(2):60-65]  
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Background  
Tuberculosis (TB) is one of the oldest diseases known to 
affect humans, infects approximately one third of the 
world’s population (1, 2). The World Health 
Organization (WHO) in 2015 reported that there were an 
estimated 9.6 million new TB cases and 1.5 million 
deaths (3). Regardless of having highly efficacious 
treatment for decades, TB remains the main public health 
problem (1, 2).  
  
Ethiopia is highly affected by the TB pandemic and is 
ranked seventh among the 22 high-burden TB countries  
worldwide (4-6). The nation is one of the high TB, 
TB/HIV and MDR-TB countries listed [3].The global 
priorities for TB care and control are to improve early 
case-detection and treatment. Delayed diagnosis of TB is 
a major factor to the continued transmission and failure 
to the successful TB treatment outcome reported (7). The 
emergence of MDR-TB is a significant challenge for TB 
control and prevention programme (8). The increased in 
MDR-TB and extensively drugresistant TB (XDR-TB) 
incidence in Ethiopia highlighted the urgent need for 
rapid diagnostic methods (3, 9, 10). However, rapid 
detection and  
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diagnosis of   MD/X/R-TB is less practiced due to 
shortage of laboratory facilities.  In Ethiopia, sputum 
smear microscopy remains the most common method for 
diagnosing TB. However, smear microscopy lacks 
sensitivity (11, 12). Culture for Mycobacterium species 
is not available as routine tests in Ethiopia.Thus, the use 
of simple, rapid molecular tests to diagnose TB and 
drug-resistant TB is important. The WHO endorsed the 
use of the Xpert assay in 2010.  The assay detects 
simultaneously M. tuberculosis and its RIF resistance, 
which is commonly considered as a surrogate marker of 
MDR-TB (10). The assay provides results directly from 
clinical specimens in less than 2 hours (10, 11). 
According to WHO report of the year 2015, most 
developing countries are using Xpert test for the 
diagnosis of presumptive MDR-TB and people living 
with HIV (3). In the studied areas, Xpert test was 
implemented since 2015. Thus, the objective of this 
study was to assess the preliminary implementation of 
GeneXpert assay in the diagnosis of TB and its RIF 
resistance at FHRH and DGH hospitals, located about 
100km far apart, in Amhara Regional State, Northwest 
part of Ethiopia.  
  
Methods  
Study design, setting and data collection:  A 
retrospective cross-sectional study on records of 1922 
clinically suspected TB patients were performed. 
Records of patients who have submitted sputum sample 
for GeneXpert analysis and met the definition of 
presumptive TB and MDR-TB were included in the 
study. The study was conducted at FHRH and DTGH, 
Northwest Ethiopia. These two hospitals are among the 
busiest hospitals in Northwest Ethiopia that provide 
referral health services including TB diagnosis and 
treatment.  
  
All patients who presented from 1 November 2015 to 30 
April 2016 and had registered data on their sex, age, HIV 
status, presumptive MDR-TB status and Xpert results 
were included for analysis. Patient records that missed 
either of these variables were excluded from the 
analysis. Data were retrieved directly from GeneXpert 
result registration log book using data extraction sheet 
on 1-30 April, 2016.  
  
Xpert MTB/RIF testing:  Sputum samples were 
collected and processed directly to Xpert test (Version 
4), according to the manufacturer’s instructions. The 
sample reagent was added in a 2:1 ratio (i.e. 1.5ml of 
bactericidal sample reagent with 0.5ml of specimen) to 
unprocessed specimens in 15 ml falcon tube and the tube 
was manually agitated twice during a 15 minute 
incubation period at room temperature. Then 2 ml of the 
inactivated material was transferred to the test cartridge 
by a sterile disposable pipette. Cartridges were loaded 
into the Xpert assay device and the results were 
interpreted as previously described (10, 11). 
Invalid/error results were repeated and the final results 
were registered. Laboratory staffs in FHRH and DTGH 
were trained how to use the Xpert modules and 
cartridges including specimen handling, management of 
invalid or error results, new recording and reporting 
tools, and the interpretation of results as per the standard 
protocol.  
  
Statistical analysis:  All data were entered, cleaned, and 
analyzed using SPSS statistical software package 
version 22. Descriptive statistics was used to determine 
differences within the data of variables. Associations 
between Xpert results and patients’ age, sex, HIV status 
and presumptive MDR–TB status were determined using 
Chi-square test. A P-value of < 0.05 was considered 
statistically significant.   
Operational definition: According to the standard 
definitions of the National Tuberculosis and Leprosy 
Control Program guideline (NLCP) adopted from the 
WHO (12); Presumptive MDR-TB is a diagnosis given 
to patients with a high risk of MDR-TB and a clinical 
decision has been made to start MDR-TB treatment 
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before drug sensitivity testing results are available. 
MDR-TB on the other hand is infection caused by 
bacteria that are resistant to treatment with at least two 
of the most powerful first-line anti-TB drugs, isoniazid 
(INH) and rifampicin (RIF).  
  
Ethical approval: Permission and ethical clearance was 
obtained from Amhara Regional Health Bureau 
Institutional Review Board (IRB) at Bahir Dar Regional 
Health Research Laboratory Center to utilize the data. 
As the data was collected retrospectively, no patient’s 
details linked to the patient identity like names were used 
and confidentiality was maintained.  
  
Results  
A total of 1922 presumptive TB patients eligible for 
GeneXpert MTB/RIF assay were retrospectively 
included in this study. Among these, 1005 (52.3%) were 
males. The mean age of patients was 31.1 years with 
standard deviation of 17.5 years (range from 1- 87 
years).  Children in the age range of 0-14 years were at 
542 (28.2%). Of all the study participants, 888 (46.2%) 
of them were HIV infected (Table 1).  
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Table 1: Socio-demographic and HIV status of study participants at FHRH and DTGH, 2016.  
Variables  Number (%)    
Age category in years  





Total   
542 (28.2)  
308 (16.0)  
585(30.4)  
366 (19.0)  
121 (6.3)  









SD 17.5  
Range:  1- 
87 years  
HIV status  
Yes  
No  
Unknown   
  
888 (46.2)  
520 (27.1)  





    
  
Overall, among the total study participants with positive, RIF-susceptible, M. tb-positive, RIF- resistant presumptive 
TB cases processed using Xpert test, 258 and M. tb-positive, RIF- indeterminate were found to (14.6%) of them 
were positive for TB (prevalence was be at 211 (81.8%), 24 (9.3%) and 23 (8.9%),  calculated only from valid runs). 
Of these M. tb- respectively (Table 2).  
  
Table 2: Xpert test result of study participants at FHRH and DTGH, 2016.  
Sex   
Male  
Female  
Total   
  
1005 (52.3)  
917 (47.7)  
1922 (100)  
    
Total  1922 (100)    
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  FHRH, % (N)  DTGH, % (N)  Total, % (N)   
* Prevalence of TB was calculated from valid runs ((211+24+23)/ (1922-157))  
** Prevalence of RIF resistance was calculated from total positive runs (24/ (211+24+23))  
  
In this study, around 81.0% (1556/1922) of the status among new cases at 1054 (54.8%) followed by suspected TB 
patients were clinically diagnosed with the relapse cases at 348 (18.1%) and the treatment after MDR-TB. Hence, 
we observed presumptive MDR-TB failure at 102 (5.3%) (Table 3).  
  
Table 3: Frequency of presumptive DR-TB based on clinical grounds at FHRH and DTGH, 2016.  




Presumptive DR-TB   
New case  1054   
Relapse  348   
Treatment after lost to  4   
follow up   
54.8   
18.1   
0.2   
  Treatment after failure   102   5.3   
 MDR contact  8   0.4   
 Other  40   2.1   
 No result  366   19.0   
Total  1922   100.0   
  
However, among 258 TB positive cases detected using 
Xpert test, only 9.3% (24/258) of them were found to be 
RIF resistant. Among the total RIF resistant cases 
detected 41.7% (10/24) of them were new and 29.2% 
(7/24) of them were relapsed TB cases. The Xpert test 
result among presumptive DR-TB groups showed 
statistical significant difference (p=0.000) (Table 2 and 







Higher proportion of M. tb-positive results were 
documented among male patients at 58.5% (151/258), in 
the age group of 30-44 at 33.3% (86/258), new 
presumptive MDR-TB suspects at 39.9% (103/258) and 
HIV infected cases at 41.9% (108/258). The different 
Xpert results showed statistical significant difference 
among the different age groups (p=0.000), sex (p 
=0.009), HIV status (p=0.003) and presumptive MDR-
TB status (p=0.000) (Table 4).  
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Table 4: Xpert MTB/RIF assay result of study participants at FHRH and DTGH, 2016.  
Variables GeneXpert results P- value  
*T  RR  TI  N  I  Total  
Sex                
   Male 127 17 7 773 81 1005 0.009  
   Female  84  7  16  734  76  917  
Age category                
   0-14  31  1  5  461  44  542      15-29  53  7  4 
 208  36  308    
   30-55 69 8 9 462 37 585 0.000  
   45-64  42  5  4  282  33  366    >65  16  3 
 1  94  7  121  
   Total  211  24  23  1507  157  1922  
HIV status                
   Yes  85  8  15  699  81  888    
   No 77 12 5 393 33 520 0.003  
   Unknown  49  4  3  415  43  514  
   Total  211  24  23  1507  151  1922  
              
Presumptive DR-TB                
   **N 84 10 9 866 85 1054     R 66 7 6 240 29 348   
   L  1  0  0  2  1  4    
Number of total samples processed  544   1378   1922    
M. tuberculosis-positive, RIF- susceptible  80.9 (76/94)   82.3 (135/164)  81.8  (211/258)*   
M. tuberculosis-positive, RIF- resistant  11.7 (11/94)  7.9 (13/164)  9.3 (24/258)**   
M. tuberculosis-positive, RIF- indeterminate  7.4 (7/94)  9.8 (16/164)  8.9 (23/258)   
M. tuberculosis negative  81.2 (407/501)  87.0 (1100/1264)  85.4 (1507/1765)   
Invalid/error results  43   114  8.2 (157/1922)   
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   F  27  2  2  63  8  102    
   MDR contact 0 1 0 7 0 8 0.000  
   Other  6  0  0  33  1  40  
   No result  27  4  6  296  33  366  
   Total  211  24  23  1507  157  1922  
*T: M. tuberculosis-positive, RIF susceptible, RR: M. tuberculosis-positive, RIF- Resistant,   
TI: M. tuberculosis-positive, RIF- indeterminate, N: M. tuberculosis negative, I: Invalid/error results  
**N: new cases, R: relapse, L: lose to follow up, F: treatment failure  
  
Discussion  
Identification of drug resistant testing of Mycobacterium 
species remains a challenge in Ethiopia due to limited 
laboratory facilities. In the studied area, the laboratory 
diagnosis of TB remains mainly in a stage of Ziehl 
Nielseen (ZN) smears. However, ZN smear lacks 
sensitivity. This might have implications on wrong 
patient management, improper use of antiTB drugs and 
development of drug resistance (5, 13). In TB endemic 
areas like Ethiopia, Xpert test can serve as a sensitive 
and time saving diagnostic modality for detection of TB 
(14). Moreover, Xpert offers an opportunity for timely 
and accurate initiation of TB treatment and shortened 
time of diagnosis in highburden settings (15, 16). In this 
study, 1922 TB suspected cases had clinical results 
indicative of TB. Among these, we documented overall 
prevalence of TB diagnosed using Xpert test at 258 
(14.6%). Of which, prevalence of RIF resistance 
detected using Xpert test was found to be at 9.3 %, which 
is comparable with previous reports from Northwestern 
Ethiopia and national wide survey in Ethiopia (17, 18). 
Similar findings were also reported from the studies 
conducted on Xpert test in Ethiopia and elsewhere in the 
world ranged from 19.4%-45.3% (19-21). On the other 
hand, it is lower than the finding from Bahir Dar (22). 
Another study in Nigeria reported a RIF resistance at 6% 
(23).  The possible explanation for this difference could 
be due to the fact that this study was conducted at the site 
where TB patients were less likely served for medical 
attention and most likely they have accustomed to visit 
nearby and relatively advanced health institutions. In 
addition, the design of the study including factors such 
as sample size, type and volume of specimen used might 
be reasons for the discrepancies in Xpert test results.  
  
In this study, TB-HIV co infection rate was at 41.9% 
(108/258). The 2015 WHO report estimated a 10% 
TB/HIV co-infection in Ethiopia (3), which is much 
lower than the above findings at 41.9%. The HIV 
infected patients are one of the eligible groups 
recommended to be tested by the Xpert test for TB and 
DR-TB (10). This might be the possible reason that 
could explain the above disparity. However, similar 
other studies elsewhere in the world have reported at 
36.3% of TB/HIV co- infection using the Xpert test (24). 
Furthermore, in northern Ethiopia TB/HIV coinfection 
was reported at 11.4% (25), in Brazil at 39.0% (26), and 
Western Kenya at 55.5% (27). Although there was no 
additional information (like CD4 count and treatment 
use) about the HIV infected individuals in our sample, 
the fairly high prevalence of TB among HIV/AIDS 
patients seeks care and prompt treatment.  
  
MDR-TB is more difficult and costly than normal TB to 
treat, and is more often fatal. Culture based drug 
susceptibility testing method can provide definitive 
results, but are labour intensive and time consuming, 
usually requires at least 14 days for primary isolation of 
the organism and another 14 days for drug susceptibility 
test (28).  Furthermore, clinical diagnosis of drug 
resistance TB is difficult. Thus, molecular methods that 
target drug resistance are a suitable approach for a rapid 
drug susceptibility testing (12). In this study, based on 
clinical diagnosis 81.0% (1556/1922) of the cases were 
considered MDR-TB.  
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However, Xpert test detected only 9.3% RIF resistance. 
This implies that, the result obtained from the Xpert test 
in this study has prevented unnecessary treatment of 
cases, which has great advantage for the patient in terms 
of avoiding drug toxicity, improper use of antiTB drugs 
and development of drug resistance. Furthermore, the 
Xpert test might contributed for TB prevention and 
control through the rapid diagnosis and eventual 
treatment of TB and its associated drug resistance.  The 
rapid diagnosis of RIF resistance potentially allows TB 
patients to start on effective treatment much sooner than 
waiting for results from other types of drug susceptibility 
testing. It is also supported by the fact that the 
information provided by the Xpert test also contributed 
to cost savings by avoiding unnecessary treatment and 
aids in selecting appropriate treatment regimens and 
reaching infection control decisions quickly (29).  
  
Although it was not the objective of this study, the 
authors did not use the standard diagnostic techniques to 
compare Xpert test sensitivity, specificity and predictive 
values. Hence, the main limitations of our study were the 
lack of culture result (as no culture facility), chest X- 
rays and smear result findings which might have 
determinant factor for comparative performance study. 
However, our study was the only one report that provides 
baseline information concerning on the implementation 
of the Xpert test at FHRH and DTGH.  
  
Conclusions  
The study has clearly brought to light that there has been 
high magnitude of TB and a high prevalence of HIV 
infection in this TB cohort. Similarly in the studied area, 
81.0% patients were presumptively diagnosed with 
MDR-TB. However, Xpert detected only 9.3% RIF 
resistance cases. Improving TB detection rates and 
further reducing the burden of disease in the study site in 
particular and Ethiopia in general will require 
optimization of the current laboratory system as well as 
the introduction of new diagnostic technologies like 
Xpert test with improved sensitivities and specificities. 
Therefore, it is important to sustain and scale up the use 
of Xpert test for rapid diagnosis of TB and RIF resistance 
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at the target hospitals and other similar health facilities 
in the region.  
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